Orthopaedic Research UK and Embryo Ventures have formed Novara Therapeutics. The joint venture company will commercialize a “bone-targeting” contrast agent that improves the quality of normative diagnostic imaging, which is particularly applicable to the diagnosis and treatment of osteoporosis.

Contrast agents, often used to improve medical imaging quality, commonly lack tissue specificity and the ability to provide therapeutic action. The Novara agent aims to specifically support the diagnostic and interventional procedures of osteoporotic fractures.